How Much Weight Should You Lose Per Week on Wegovy?

Free consultation, reviewed the same day by a GPhC-registered Independent Prescriber
Your prescription, treatment and a tracked DPD delivery — all included in one price
Order before 12pm Monday to Friday and, once clinically approved, your treatment goes out the same day
Priority aftercare seven days a week, with no subscription and no auto-renewals

Most adults lose between 0.5 and 1.5 pounds per week on Wegovy, though the rate varies considerably by dose, how long you've been on treatment, and individual biology. Weekly loss tends to be fastest in the first few months, then settles. Wegovy (semaglutide) is a prescription-only medicine; how much weight you should lose on a weekly basis is something a prescriber considers alongside your starting weight, health history and how you're tolerating treatment — not a target you set independently. If you're tracking your weekly number and wondering whether it's 'enough', you're probably at a point most people on Wegovy reach around month two or three, and the question is a fair one to bring to your clinical team.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the evidence actually says, and how private pricing fits around it

Step 1: understand what a realistic weekly loss looks like on semaglutide

The STEP 1 trial (published in the New England Journal of Medicine) ran for 68 weeks and found an average body-weight reduction of around 15% at the 2.4mg maintenance dose. Spread across that period, that works out to roughly 0.5–0.9 kg per week on average, but the pattern is not a flat line. Losses are typically steeper in months one through four, then taper as your body adjusts. Weeks where the number barely moves are common and don't signal failure.

The NHS tirzepatide and semaglutide medicines pages reinforce that weight loss is progressive and individual. Some people lose more slowly; some see a faster early drop. Comparing your week-six figure to a friend's is rarely useful.

For a more granular look at what the data shows at different stages, our page on weekly weight loss on Wegovy walks through the trial figures in detail. If you want to understand how much weight loss per week on Wegovy is typical across the different trial phases, that page breaks it down stage by stage. The short version: a weekly loss of 0.5–1.5 lbs is clinically meaningful and well within the expected range for most people on treatment.

Step 2: recognise how your dose stage affects the weekly number

Wegovy starts at 0.25mg and titrates upward over several months, reaching the 2.4mg maintenance dose. At the lower doses (0.25mg and 0.5mg) most people lose little weight per week. That's expected. Those starter doses exist to let your digestive system settle, not to produce the main weight-loss effect. The question of how much you should lose per week on Wegovy only becomes meaningful at or near the maintenance dose.

The newer 7.2mg dose (the MHRA approved a dedicated single-dose 7.2mg pen in April 2026) showed around 20.7% average weight loss over 72 weeks in trials, which narrows the gap with tirzepatide's results. Whether a specific dose or pen format is available to you is confirmed at consultation.

If you're wondering how much weight you can lose a week on Wegovy at maintenance versus earlier dose stages, that page sets out the realistic ceiling and the factors that influence it. For a broader comparison of how weekly figures translate into monthly progress, our page on monthly weight loss on Wegovy may offer a more useful frame for tracking.

Step 3: understand what the private cost of Wegovy actually covers

Private Wegovy pricing is priced per pen or per month, and varies between providers. Since Eli Lilly raised Mounjaro's UK list price in September 2025, the wider private GLP-1 market has seen upward pressure on prices too, reported private costs for semaglutide typically range depending on dose and provider, and the headline figure you see advertised is not always the full story.

What headline prices commonly leave out: the consultation fee, the prescription charge, aftercare support if you hit a side effect at 9pm, and clinical review before each repeat. Those aren't extras at every provider, but they're worth confirming before committing. It's also worth knowing that how much Wegovy costs to make is quite different from what you pay at the pharmacy, which helps explain the margin that sits between manufacturer and patient. For a clearer picture of what Wegovy costs in the UK private market, see our Wegovy price page.

At nume, one price covers everything: the consultation, the prescription, the treatment, and free next-working-day delivery by DPD in plain packaging. We are deliberately not the cheapest option available. What that buys you is a consultation read the same day by a real prescriber, not software (a named clinician, not a queue for a bot) alongside priority aftercare seven days a week. There are no subscriptions and no auto-renewals; every repeat order is reviewed before it goes out. See exactly what's included on our treatment page.

Step 4: why cheapest is the wrong measure for a prescription medicine

Wegovy is a Prescription-Only Medicine. The clinical assessment behind it matters. An offer that prices out the clinical review, skips identity verification, or arrives from a seller you can't trace to a GPhC-registered pharmacy is a risk, not a saving. The MHRA has been clear on the dangers of purchasing GLP-1 medicines from unverified sources, fake pens have caused real harm. You can check any online pharmacy's registration instantly at the GPhC pharmacy register. Our registration number is 9012878.

Price is a reasonable thing to think about when you're making a monthly commitment. Paying less per pen from a source that can't demonstrate proper clinical oversight answers the wrong question. The right question is whether you're receiving genuine medicine, proper prescribing, and a clinical team you can reach if something doesn't feel right.

For a broader look at semaglutide treatment and what it involves, our Wegovy overview covers the full picture. And if you're curious how the evidence compares across different GLP-1 options, our semaglutide weight loss page sits alongside this one.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions